BSSE spinoff Engimmune raises seed financing to develop novel T-cell receptor therapeutics

Exciting news from our youngest spinoff company: Engimmune Therapeutics completed a CHF 15.5 million seed financing round to boost R&D of novel T-​cell receptor (TCR)-​based therapeutics. Proceeds from the financing will be used to further build Engimmune’s pipeline, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-​certified manufacturing, clinical development, and regulatory affairs.